オプションチェーンは、AtriCureの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、AtriCureの市場センチメントを評価します。.

AtriCure (NASDAQ:ATRC) 株価情報, オプションチェーン

AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

AtriCure Inc

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $49 to $53.

News

Price Target

Analyst Ratings

ATRC

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $53

Oppenheimer analyst Suraj Kalia maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Outperform and raises the price target from $32 to $36.

Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to $36

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Shares of Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 13.5% to $12.38 following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41627569/snap-stock-is-surging-today-whats-going-on">quarterly financial results.</a>
Snap reported third-quarter revenue of $1.373 billion, beating the consensus estimate of $1.358 billion, according to Benzinga Pro. The social media company reported adjusted earnings of 8 cents per share, beating analyst estimates of 5 cents per share.
Snap shares jumped 13.5% to $12.38 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 41.3% to $115.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 37% to $54.99 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) surged 30.7% to $7.03 after the company reported better-than-expected third-quarter sales results and raised its FY24 non-GAAP operating profit margin guidance.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) rose 30.7% to $7.53 after the company announced that it has entered into a term sheet with TerraPower for the construction of a HALEU production facility.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) gained 27.3% to $14.41 after the company reported better-than-expected quarterly revenue results.</li>
<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) surged 23% to $36.21 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $34 to $40.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) gained 22.9% to $204.48 after the company reported better-than-expected third-quarter financial results and raised annual outlook.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) surged 14.6% to $32.92 after the company reported better-than-expected quarterly financial results and raised its FY24 sales guidance above estimates.</li>
<li>The Cheesecake Factory Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) gained 13.6% to $48.69 after the company reported better-than-expected quarterly adjusted EPS results. Also, multiple firms raised their respective price targets on the stock.</li>
<li>Adtalem Global Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NASDAQ">ATGE</a>) rose 12.7% to $84.53 following first-quarter results.</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 11.5% to $67.12 following better-than-expected quarterly earnings.</li>
<li>OneMain Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) rose 10.8% to $52.63 following strong quarterly earnings.</li>
<li>Smurfit Westrock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) gained 10.4% to $49.38 following third-quarter results.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) surged 6.2% to $129.21.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) gained 5.3% to $180.25 following better-than-expected third-quarter earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41623120/jim-cramer-says-buy-crowdstrike-stock-calls-this-aerospace-manufacturer-is-a-high-specul">Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A &#8216;High Speculative&#8217; Stock</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

ASPI

Adtalem Global Education Inc. Common Stock

ATGE

CAKE

DELL

EXEL

GOOG

GRMN

NRDS

OMCL

RDDT

SNAP

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday

JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and raises the price target from $30 to $40.

JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $40

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $35 to $40.

UBS Maintains Buy on AtriCure, Raises Price Target to $40

WIIM

Atricure shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $34 to $40.

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 21.6% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock rose 18.32% to $4.65. The company's market cap stands at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares increased by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 15.52% to $34.0. The market value of their outstanding shares is at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The market value of their outstanding shares is at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) shares increased by 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 41.7% to $0.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.9 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares fell 21.43% to $24.2. The company's market cap stands at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 19.85% to $1.05. The market value of their outstanding shares is at $56.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock fell 14.31% to $0.42. The market value of their outstanding shares is at $27.0 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares declined by 13.65% to $0.95. The company's market cap stands at $23.9 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares fell 11.92% to $9.46. The market value of their outstanding shares is at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

APDN

CALC

CVRX

ENSC

GLYC

HOOK

MTNB

SPRO

Tempest Therapeutics, Inc. - Common Stock

TPST

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 21.4% to $0.5 during Wednesday's pre-market session. The company's market cap stands at $7.5 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock increased by 18.92% to $35.0. The company's market cap stands at $1.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock increased by 18.32% to $4.65. The market value of their outstanding shares is at $49.9 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock moved upwards by 18.27% to $3.3. The company's market cap stands at $16.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 15.38% to $1.95. The company's market cap stands at $117.4 million. </li>
<li>HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) stock rose 14.47% to $4.27. The company's market cap stands at $42.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 42.2% to $0.18 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares decreased by 21.43% to $24.2. The market value of their outstanding shares is at $730.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares fell 19.12% to $1.06. The market value of their outstanding shares is at $57.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 15.94% to $0.41. The company's market cap stands at $26.5 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock declined by 14.13% to $0.94. The company's market cap stands at $23.8 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock fell 11.92% to $9.46. The company's market cap stands at $205.3 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Needham analyst Mike Matson maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $34 to $40.

Needham Maintains Buy on AtriCure, Raises Price Target to $40

<h3>Gainers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock increased by 9.9% to $3.33 during Tuesday's after-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock increased by 8.82% to $0.37. The company's market cap stands at $2.6 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 6.3% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 5.37% to $0.31. The company's market cap stands at $16.8 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares rose 5.33% to $0.74. The company's market cap stands at $9.1 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock rose 5.33% to $31.0. The market value of their outstanding shares is at $1.5 billion. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) shares declined by 11.2% to $15.01 during Tuesday's after-market session. The company's market cap stands at $792.6 million. </li>
<li>DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) stock decreased by 8.25% to $145.25. The market value of their outstanding shares is at $12.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares declined by 7.93% to $2.79. The market value of their outstanding shares is at $7.0 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares decreased by 7.7% to $0.28. The market value of their outstanding shares is at $3.7 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 7.09% to $5.51. The market value of their outstanding shares is at $2.7 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock decreased by 6.59% to $14.75. The market value of their outstanding shares is at $1.7 billion. The company's, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

APVO

CYCN

LGMK

MRNS

RSLS

SNES

TYRA

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Atricure shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

Guidance

ArtiCure Sees FY24 Revenue ~$459M-$462M Vs $458.111M Est; Adj. EPS ($0.80)-($0.74) Vs $(0.79) Est.

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $115.910 million which beat the analyst consensus estimate of $112.254 million by 3.26 percent. This is a 17.93 percent increase over sales of $98.290 million the same period last year.

Earnings

Earnings Beats

AtriCure Q3 2024 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $115.910M Beat $112.254M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54135844&amp;newsitemid=20241015227939&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=ec2160bde95edd90149ea3225f0f0ccc">AtriCure, Inc.</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;,%20esheet=54135844&amp;,%20newsitemid=20241015227939&amp;,%20lan=en-US&amp;,%20anchor=Nasdaq%3A+ATRC&amp;,%20index=2&amp;,%20NASDAQ:%3Ca%20class=">ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX&#x2122;cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block&#x2122; therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation cryoSPHERE&#xAE; cryoablation probe, and over 30% when compared to the cryoSPHERE&#xAE;+ probe.

Biotech

General

AtriCure Announces Launch Of cryoSPHERE MAX Probe For Post-Operative Pain Management

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Atricure.com&amp;esheet=54113283&amp;newsitemid=20240827359775&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=18e0f9147650ec01358e204c7f81ae96">AtriCure, Inc.</a> ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=http%3A%2F%2Fir.atricure.com%2Fphoenix.zhtml%3Fc%3D189981%26p%3Dirol-irhome&amp;,%20esheet=54113283&amp;,%20newsitemid=20240827359775&amp;,%20lan=en-US&amp;,%20anchor=Nasdaq%3A+ATRC&amp;,%20index=2&amp;,%20NASDAQ:%3Ca%20class=">ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip&#xAE; FLEX-Mini&#x2122; device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of AtriCure's AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians.

AtriCure Reports First Patient Has Been Treated With The Revolutionary AtriClip FLEX-Mini Device

AtriCure, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atrc#NASDAQ">ATRC</a>) recently announced the receipt of an expanded indication for the AtriClip&nbsp;in CE-marked countries in&nbsp;Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted.
The European Commission&#39;s expanded indication is based on AtriCure&#39;s clinical findings that patients who are at high risk of thromboembolism can experience fewer strokes with AtriClip.The company expects significant growth potential for the use of mechanical appendage closure.
<h2>More on the News</h2>
The LAA is a major source of blood clots in patients with atrial fibrillation (Afib), and the AtriClip device series represents a novel approach to electrically isolate, exclude, and ultimately remove the LAA in the course of heart surgery.
More than 85 peer-reviewed papers on the short- and long-term safety and effectiveness of AtriClip devices have been published since the device initially went into use in 2007. This amounts to more than 11,000 patients who were investigated in various regions. The ArtiClip devices, which are already driving revenues in the United States, are likely to generate more international revenues after the expansion of the CE- Mark indication.
In July 2024, AtriCure announced that it had received regulatory approval from the&nbsp;National Medical Products Administration of&nbsp;China&nbsp;to market and sell several models of its AtriClip&nbsp;LAA Exclusion System.The company is likely to work closely with Chinese regulatory authorities to facilitate the introduction of additional innovative products in the future. This approval is expected to expand AtriCure&#39;s business globally and generate additional revenues.
<h2>Industry Prospects</h2>
Per a report by Grand View Research, the global atrial fibrillation market size&nbsp;was estimated to be $22.4 billion in 2022&nbsp;and is expected to witness a growth rate of 10.1% from 2023 to 2030.
The increasing prevalence of AFib and growing awareness about the condition are expected to drive the market. Factors such as the aging population, lifestyle changes, and the surge in chronic illnesses such as obesity and diabetes are contributing to the rising incidence of atrial fibrillation.
<h2>Product Portfolio Expansion</h2>
AtriCure, a leading innovator in surgical treatments and therapies for Afib, LAA management and post-operative pain management, boasts a strong product portfolio and plans to expand to improve patient care in the future.
In April, AtriCure launched the cryoSPHERE+&nbsp;cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure&#39;s legacy cryoSHPERE&nbsp;device. The cryoSPHERE+&nbsp;received FDA 510(k) clearance for temporarily blocking pain by ablating peripheral nerves in adult patients and by ablating intercostal nerves under direct visualization in adolescent patients.
The company is likely to advance several clinical initiatives in the second half of 2024, including its LeAAPS stroke reduction trial and introduce new products across its markets, with two cryoSPHERE probes to reduce freeze times and the most advanced, smallest profile AtriClip device.
<h2>Price Performance</h2>
In the year-to-date period, ATRC&#39;s shares have plunged 31.8% against the industry&#39;s rise of 9.1%. The S&amp;P 500 has gained 17.8% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/75176.jpg?v=1020748899" />
Image Source: Zacks Investment Research
<h2>Zacks Rank and Stocks to Consider</h2>
ATRC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service,&nbsp;Quest Diagnostics&nbsp;and&nbsp;ABM Industries. While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2326561/atricure-s-atrc-atriclip-receives-expanded-ce-mark-indication?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2326561">To read this article on Zacks.com click here.</a>

Small Cap

AtriCure's AtriClip Receives Expanded CE-Mark Indication

AtriCure Receives Expanded Indication For AtriClip In Europe For High-Risk Thromboembolism Patients, Validating Its Effectiveness In Reducing Stroke Events During Cardiac Surgery

Analysts' ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $37.17, a high estimate of $53.00, and a low estimate of $26.00. Experiencing a 16.47% decline, the current average is now lower than the previous average price target of $44.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722452497_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of AtriCure's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About AtriCure</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
<h3>Financial Insights: AtriCure</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: AtriCure's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 16.43%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AtriCure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): AtriCure's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.2%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 6 Analyst Ratings For AtriCure

BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $58 to $53.

BTIG Maintains Buy on AtriCure, Lowers Price Target to $53

JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight and lowers the price target from $34 to $30.

JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript

Atricure (ATRC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel Stauder from JMP Sec...

AtriCure's Growth Prospects and Buy Rating Despite Short-Term Challenges

Atricure (ATRC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst William Plovanic from Canac...

AtriCure's Resilience Amidst Competition: A Strong Buy Recommendation

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY – Research Report), Atricure (ATRC – Re...

Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)

Piper Sandler Remains a Buy on Atricure (ATRC)

Reports Q3 revenue $115.9M, consensus $112.25M. "Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout ou...

AtriCure reports Q3 adjusted EPS (17c), consensus (19c)

Raises FY24 revenue view tot $459M-$462M from $456M-$461M, consensus $458.11M. Published first on TheFly – the ultimate source for real-time, marke...

AtriCure narrows FY24 EPS view to (80c)-(74c) from (82c)-(74c), consensus (79c)

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript

In a report released today, Daniel Stauder from JMP Securities reiterated a Buy rating on Atricure (ATRC – Research Report), with a price target of...

AtriCure's Strong Growth and Strategic Initiatives Earn Buy Rating from Analyst Daniel Stauder

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Ne...

Comments

AtriCure

AtriCure (ATRC) オプション

AtriCure (NASDAQ:ATRC) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル